vs
Donnelley Financial Solutions, Inc.（DFIN）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Pacira BioSciences, Inc.の直近四半期売上が大きい（$177.4M vs $172.5M、Donnelley Financial Solutions, Inc.の約1.0倍）。Donnelley Financial Solutions, Inc.の純利益率が高く（3.6% vs 1.6%、差は2.0%）。Donnelley Financial Solutions, Inc.の前年同期比売上増加率が高い（10.4% vs 5.0%）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（-0.2% vs -7.9%）
Donnelley Financial Solutions（DFIN）はアメリカ合衆国イリノイ州シカゴを本拠とする金融コンプライアンス企業です。資本市場・投資市場に参入する企業に向け、米国規制に準拠したSaaS製品、ソフトウェア対応サービス、印刷業務および各種コンプライアンスサービスを提供しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
DFIN vs PCRX — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $172.5M | $177.4M |
| 純利益 | $6.2M | $2.9M |
| 粗利率 | — | — |
| 営業利益率 | 8.3% | 3.9% |
| 純利益率 | 3.6% | 1.6% |
| 売上前年比 | 10.4% | 5.0% |
| 純利益前年比 | -1.6% | — |
| EPS（希薄化後） | $0.31 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $177.4M | ||
| Q4 25 | $172.5M | $196.9M | ||
| Q3 25 | $175.3M | $179.5M | ||
| Q2 25 | $218.1M | $181.1M | ||
| Q1 25 | $201.1M | $168.9M | ||
| Q4 24 | $156.3M | $187.3M | ||
| Q3 24 | $179.5M | $168.6M | ||
| Q2 24 | $242.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $6.2M | — | ||
| Q3 25 | $-40.9M | $5.4M | ||
| Q2 25 | $36.1M | $-4.8M | ||
| Q1 25 | $31.0M | $4.8M | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $8.7M | $-143.5M | ||
| Q2 24 | $44.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 8.3% | 1.2% | ||
| Q3 25 | 16.1% | 3.5% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 22.8% | 1.2% | ||
| Q4 24 | 6.0% | 13.2% | ||
| Q3 24 | 10.1% | -82.8% | ||
| Q2 24 | 26.6% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | -23.3% | 3.0% | ||
| Q2 25 | 16.6% | -2.7% | ||
| Q1 25 | 15.4% | 2.8% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 4.8% | -85.1% | ||
| Q2 24 | 18.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.31 | $0.05 | ||
| Q3 25 | $-1.49 | $0.12 | ||
| Q2 25 | $1.28 | $-0.11 | ||
| Q1 25 | $1.05 | $0.10 | ||
| Q4 24 | $0.21 | $0.38 | ||
| Q3 24 | $0.29 | $-3.11 | ||
| Q2 24 | $1.47 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $24.5M | $144.3M |
| 総負債低いほど良い | $171.3M | — |
| 株主資本純資産 | $379.2M | $653.9M |
| 総資産 | $800.4M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.45× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $144.3M | ||
| Q4 25 | $24.5M | $238.4M | ||
| Q3 25 | $22.7M | $246.3M | ||
| Q2 25 | $33.8M | $445.9M | ||
| Q1 25 | $16.2M | $493.6M | ||
| Q4 24 | $57.3M | $484.6M | ||
| Q3 24 | $33.6M | $453.8M | ||
| Q2 24 | $35.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $171.3M | $372.2M | ||
| Q3 25 | $154.7M | $376.7M | ||
| Q2 25 | $190.1M | $580.5M | ||
| Q1 25 | $189.5M | $583.4M | ||
| Q4 24 | $124.7M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $379.2M | $693.1M | ||
| Q3 25 | $423.1M | $727.2M | ||
| Q2 25 | $432.1M | $757.8M | ||
| Q1 25 | $419.9M | $798.5M | ||
| Q4 24 | $436.1M | $778.3M | ||
| Q3 24 | $444.5M | $749.6M | ||
| Q2 24 | $441.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $800.4M | $1.3B | ||
| Q3 25 | $816.3M | $1.3B | ||
| Q2 25 | $874.7M | $1.5B | ||
| Q1 25 | $852.8M | $1.6B | ||
| Q4 24 | $841.6M | $1.6B | ||
| Q3 24 | $843.6M | $1.5B | ||
| Q2 24 | $882.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | 0.54× | ||
| Q3 25 | 0.37× | 0.52× | ||
| Q2 25 | 0.44× | 0.77× | ||
| Q1 25 | 0.45× | 0.73× | ||
| Q4 24 | 0.29× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.8M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $47.9M | — |
| FCFマージンFCF / 売上 | 27.8% | — |
| 設備投資強度設備投資 / 売上 | 6.9% | — |
| キャッシュ転換率営業CF / 純利益 | 9.65× | — |
| 直近12ヶ月FCF直近4四半期 | $107.8M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $59.8M | $43.7M | ||
| Q3 25 | $74.4M | $60.8M | ||
| Q2 25 | $68.4M | $12.0M | ||
| Q1 25 | $-37.7M | $35.5M | ||
| Q4 24 | $56.4M | $33.1M | ||
| Q3 24 | $86.4M | $53.9M | ||
| Q2 24 | $56.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $47.9M | $43.5M | ||
| Q3 25 | $59.2M | $57.0M | ||
| Q2 25 | $51.7M | $9.3M | ||
| Q1 25 | $-51.0M | $26.9M | ||
| Q4 24 | $41.3M | $31.0M | ||
| Q3 24 | $67.3M | $49.8M | ||
| Q2 24 | $36.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 27.8% | 22.1% | ||
| Q3 25 | 33.8% | 31.7% | ||
| Q2 25 | 23.7% | 5.1% | ||
| Q1 25 | -25.4% | 15.9% | ||
| Q4 24 | 26.4% | 16.6% | ||
| Q3 24 | 37.5% | 29.6% | ||
| Q2 24 | 15.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 8.7% | 2.2% | ||
| Q2 25 | 7.7% | 1.5% | ||
| Q1 25 | 6.6% | 5.1% | ||
| Q4 24 | 9.7% | 1.1% | ||
| Q3 24 | 10.6% | 2.4% | ||
| Q2 24 | 8.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 9.65× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 1.89× | — | ||
| Q1 25 | -1.22× | 7.37× | ||
| Q4 24 | 8.95× | — | ||
| Q3 24 | 9.93× | — | ||
| Q2 24 | 1.27× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
